Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Assets (2016 - 2025)

Historic Return on Assets for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 0.52%.

  • Viridian Therapeutics, Inc.\DE's Return on Assets fell 1400.0% to 0.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.52%, marking a year-over-year decrease of 1400.0%. This contributed to the annual value of 0.44% for FY2024, which is 800.0% up from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Return on Assets stood at 0.52%, which was down 1400.0% from 0.55% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Return on Assets high stood at 0.3% for Q4 2022, and its period low was 1.1% during Q2 2021.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's Return on Assets averaged around 0.53%, with its median value being 0.45% (2022).
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Return on Assets soared by 9800bps in 2021 and then plummeted by -2800bps in 2023.
  • Viridian Therapeutics, Inc.\DE's Return on Assets (Quarter) stood at 0.37% in 2021, then grew by 21bps to 0.3% in 2022, then crashed by -96bps to 0.58% in 2023, then skyrocketed by 39bps to 0.36% in 2024, then tumbled by -46bps to 0.52% in 2025.
  • Its Return on Assets was 0.52% in Q3 2025, compared to 0.55% in Q2 2025 and 0.44% in Q1 2025.